Gilead Sciences | GILD - Current Liabilities

Stock Price
130.36
Daily Change
-3.28 -2.45%
Monthly
-5.71%
Yearly
26.35%
Q2 Forecast
134.61

Gilead Sciences reported $11.81B in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
ALKERMES USD 543.44M 69.08M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Glaxosmithkline GBP 28.82B 144.79M Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
J&J USD 57.72B 3.59B Mar/2026
Merck USD 28.63B 2.59B Sep/2025
Moderna USD 1.99B 306M Dec/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Novartis USD 27.28B 4.72B Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 30.01B 1.66B Mar/2026
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
United Therapeutics USD 560.6M 14.3M Dec/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025